Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Ibrance by Pfizer for Renal Cell Carcinoma: Likelihood of Approval
Ibrance is under clinical development by Pfizer and currently in Phase II for Renal Cell Carcinoma. According to GlobalData, Phase...
Ibrance by Pfizer for Metastatic Breast Cancer: Likelihood of Approval
Ibrance is under clinical development by Pfizer and currently in Phase III for Metastatic Breast Cancer. According to GlobalData, Phase...
Ibrance by Pfizer for Papillary Renal Cell Carcinoma: Likelihood of Approval
Ibrance is under clinical development by Pfizer and currently in Phase II for Papillary Renal Cell Carcinoma. According to GlobalData,...
Ibrance by Pfizer for Rhabdomyosarcoma: Likelihood of Approval
Ibrance is under clinical development by Pfizer and currently in Phase II for Rhabdomyosarcoma. According to GlobalData, Phase II drugs...
Ibrance by Pfizer for Fallopian Tube Cancer: Likelihood of Approval
Ibrance is under clinical development by Pfizer and currently in Phase II for Fallopian Tube Cancer. According to GlobalData, Phase...
Ibrance by Pfizer for Metastatic Brain Tumor: Likelihood of Approval
Ibrance is under clinical development by Pfizer and currently in Phase II for Metastatic Brain Tumor. According to GlobalData, Phase...
Ibrance by Pfizer for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
Ibrance is under clinical development by Pfizer and currently in Phase III for Head And Neck Squamous Cell Carcinoma (HNSC)....
Ibrance by Pfizer for Pediatric Diffuse Intrinsic Pontine Glioma: Likelihood of Approval
Ibrance is under clinical development by Pfizer and currently in Phase II for Pediatric Diffuse Intrinsic Pontine Glioma. According to...
Ibrance by Pfizer for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
Ibrance is under clinical development by Pfizer and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to GlobalData,...
Ibrance by Pfizer for Epithelial Ovarian Cancer: Likelihood of Approval
Ibrance is under clinical development by Pfizer and currently in Phase II for Epithelial Ovarian Cancer. According to GlobalData, Phase...
Ibrance by Pfizer for Medulloblastoma: Likelihood of Approval
Ibrance is under clinical development by Pfizer and currently in Phase II for Medulloblastoma. According to GlobalData, Phase II drugs...
Ibrance by Pfizer for Non-Small Cell Lung Cancer: Likelihood of Approval
Ibrance is under clinical development by Pfizer and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData,...
Ibrance by Pfizer for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval
Ibrance is under clinical development by Pfizer and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to...
Ibrance by Pfizer for Metastatic Colorectal Cancer: Likelihood of Approval
Ibrance is under clinical development by Pfizer and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData, Phase...
Ibrance by Pfizer for Chordoma: Likelihood of Approval
Ibrance is under clinical development by Pfizer and currently in Phase II for Chordoma. According to GlobalData, Phase II drugs...
Ibrance by Pfizer for Peritoneal Cancer: Likelihood of Approval
Ibrance is under clinical development by Pfizer and currently in Phase II for Peritoneal Cancer. According to GlobalData, Phase II...
Ibrance by Pfizer for Ewing Sarcoma: Likelihood of Approval
Ibrance is under clinical development by Pfizer and currently in Phase II for Ewing Sarcoma. According to GlobalData, Phase II...
Ibrance by Pfizer for Neuroblastoma: Likelihood of Approval
Ibrance is under clinical development by Pfizer and currently in Phase II for Neuroblastoma. According to GlobalData, Phase II drugs...
Ibrance by Pfizer for Endometrial Cancer: Likelihood of Approval
Ibrance is under clinical development by Pfizer and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase II...
Ibrance by Pfizer for Refractory Acute Myeloid Leukemia: Likelihood of Approval
Ibrance is under clinical development by Pfizer and currently in Phase I for Refractory Acute Myeloid Leukemia. According to GlobalData,...